bluebird bio, Inc. - Common Stock (NQ:BLUE)

4.970 UNCHANGED

Last Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about bluebird bio, Inc. - Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

22 23 Next >

Why is Bluebird Bio (BLUE) Stock Down 9% Today? ↗

January 18, 2023

Bluebird Bio (BLUE) stock is slipping on Wednesday after the biotechnology company announced a proposed public offering.

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

January 18, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

January 18, 2023

We're starting the day with a breakdown of the biggest pre-market stock movers traders will want to watch on Wednesday morning!

Via InvestorPlace

bluebird bio, Inc. Announces Proposed Public Offering of Common Stock

January 18, 2023

From bluebird bio, Inc.

Via Business Wire

2 Risky Stocks That Could Soar in 2023 ↗

December 06, 2022

These "exciting" companies aren't for everyone.

Via The Motley Fool

Looking Into bluebird bio's Return On Capital Employed ↗

November 30, 2022

Via Benzinga

Analyst Ratings for bluebird bio ↗

November 08, 2022

Within the last quarter, bluebird bio (NASDAQ:BLUE) has observed the following analyst ratings:

Via Benzinga

bluebird bio Provides Update on Commercial Launch Progress, Program Milestones and 2023 Financial Outlook Ahead of Company Presentation at 41st Annual J.P. Morgan Healthcare Conference

January 09, 2023

From bluebird bio, Inc.

Via Business Wire

2 Stocks That Could Double Your Money in 2023 ↗

January 07, 2023

These biotechs could crush the market, but there is more to the story.

Via The Motley Fool

bluebird bio Sells Second Priority Review Voucher for $95 Million

January 06, 2023

From bluebird bio, Inc.

Via Business Wire

Newly Approved Drugs In US Command Over $200,000 On An Average ↗

January 05, 2023

The median annual price of 17 new drugs approved by the FDA since July 2022 reached $193,900, down from $257,000 in 1H of 2022. For the full year 2022, the median price was $222,003.

Via Benzinga

bluebird bio to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 05, 2023

From bluebird bio, Inc.

Via Business Wire

bluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer

January 03, 2023

From bluebird bio, Inc.

Via Business Wire

1 Cathie Wood Stock to Buy While It's Affordable, and 1 to Avoid (for Now) ↗

December 30, 2022

Both stocks have fallen brutally this year, but only one has a chance to recover soon.

Via The Motley Fool

After Doubling in the Past 6 Months, Is This Stock a Buy? ↗

December 24, 2022

This company has had a solid year, but there is still plenty of work ahead.

Via The Motley Fool

FDA Allows Bluebird Bio To Resume Sickle Cell Disease Studies In Patients Below 18, With Changed Protocol ↗

December 19, 2022

Via Benzinga

BLUE Stock Alert: What to Know as the FDA Lifts Hold on Bluebird Bio Treatment ↗

December 19, 2022

In a counterintuitive move, traders are selling BLUE stock even as Bluebird Bio claims to be on track with its sickle cell disease treatment.

Via InvestorPlace

FDA Lifts Partial Clinical Hold for bluebird bio’s Sickle Cell Disease (SCD) Studies for Patients Under the Age of 18

December 19, 2022

From bluebird bio, Inc.

Via Business Wire

Magenta Therapeutics Shares Surge After Encouraging Data From Blood Cancer Candidate At ASH Meeting ↗

December 13, 2022

Via Benzinga

Why Bluebird Bio Stock Crushed the Market Today ↗

December 12, 2022

The company looks set to continue its good momentum in the early part of next year.

Via The Motley Fool

New Data from bluebird bio’s Gene Therapies for Transfusion-Dependent Beta-Thalassemia and Sickle Cell Disease Presented at 64th ASH Annual Meeting

December 10, 2022

From bluebird bio inc.

Via Business Wire

What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers

December 06, 2022

Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds.

Via TheNewswire.com

What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers

December 06, 2022

By Ernest Dela Aglanu, Benzinga

Via News Direct

Why CSL Ltd Stock Could Be Worth a Look

December 03, 2022

FDA approval of costly--but worthwhile--drug leads the momentum that could make CSL Ltd an equally worthwhile investment.

Via MarketBeat

Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position ↗

November 30, 2022

Via Benzinga

bluebird bio Sells Priority Review Voucher for $102 Million

November 30, 2022

From bluebird bio, Inc.

Via Business Wire

FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults ↗

November 23, 2022

Via Benzinga

Where Will Editas Medicine Be in 1 Year? ↗

November 20, 2022

The company could continue lagging the market for a while.

Via The Motley Fool

2 Growth Stocks That Could Double in 2023 ↗

November 17, 2022

Both are lagging the market this year.

Via The Motley Fool

Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday ↗

November 08, 2022

Gainers

Via Benzinga

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.